Walmart has agreed to pay $50 million to resolve a major U.S. government lawsuit accusing the retail giant of improperly handling opioid prescriptions through its pharmacies.
The settlement brings an end to a case in which the government had once warned that Walmart could face billions of dollars in civil penalties. Walmart, however, has not admitted wrongdoing and described the settlement payment as immaterial in a regulatory filing.
The case, filed in December 2020, centered on allegations that Walmart pharmacies repeatedly violated federal requirements governing controlled substances. The government claimed the company failed to respond appropriately to warning signs surrounding potentially suspicious opioid prescriptions.
According to the allegations, some Walmart compliance personnel were aware that certain prescribers were allegedly operating so-called “pill mills,” yet prescriptions linked to them continued to be filled.
The Justice Department had portrayed the lawsuit as one of its most significant actions against an individual company in connection with the opioid crisis.
Under the agreement, Walmart will also introduce additional safeguards involving its pharmacists. The company is required to strengthen oversight and establish a hotline through which employees and patients can report suspected unlawful dispensing of opioid medications.
Walmart said it was pleased to resolve the federal case and emphasized the role of its pharmacists in providing patient care.
The $50 million payment is considerably smaller than the potential penalties that had been discussed when the government launched its case. Walmart reported net income of $11.7 billion for the six months ending July 31, underscoring why the company characterized the settlement as immaterial.
The federal case is separate from a much larger series of claims brought by state and local governments. In 2022, Walmart agreed to pay $3.1 billion to resolve thousands of lawsuits alleging that its pharmacies contributed to the opioid crisis. Other major pharmacy chains, including CVS and Walgreens, reached their own substantial settlements.
A Narrower Case Before Settlement
The federal lawsuit had already been significantly reduced before the settlement was reached.
In March 2024, a federal judge dismissed allegations that Walmart had failed to report suspicious prescriptions to the Drug Enforcement Administration and that its pharmacists had failed to properly document warning signs connected to prescriptions.
Two allegations remained. One concerned prescriptions allegedly dispensed even though Walmart compliance personnel knew they were invalid. The other involved pharmacists allegedly dispensing prescriptions they themselves knew were invalid.
A joint filing seeking dismissal of the case was submitted in federal court in Wilmington, Delaware, bringing the long-running dispute to a close.
The settlement comes against the backdrop of an opioid epidemic that has claimed hundreds of thousands of lives in the United States. More than 905,000 people died from opioid overdoses between 1999 and 2025, according to U.S. health authorities, although annual overdose deaths began falling after 2022.
Walmart’s resolution adds another major corporate settlement to the long-running legal fallout from the opioid crisis, while allowing the retailer to end the federal dispute without acknowledging liability.
